How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

593 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Genome-wide differential expression profiling of long non-coding RNAs in androgenetic alopecia in a Chinese male population. (PubMed)

Genome-wide differential expression profiling of long non-coding RNAs in androgenetic alopecia in a Chinese male population. Androgenetic alopecia (AGA), or male pattern baldness (MPB), is the most common form of hair loss in males. A combination of genetic and androgen causes have been suggested as factors that contribute to the development of AGA. However, the specific molecular mechanisms that underly AGA remain largely unknown. Long non-coding RNAs (lncRNAs), a new class of regulatory non

2017 Journal of the European Academy of Dermatology and Venereology

62. Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). (PubMed)

as compared with sham-treated control patients in this multicenter randomized controlled trial.These results suggest that the emerging technology of low-level laser therapy may play a potentially significant role in health care providers' armamentarium for the disease androgenic alopecia. (...) Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). Photobiomodulation, also referred to as low-level laser therapy (LLLT), has been studied and used for (among other diseases) the promotion of hair regrowth.A clinical study was developed to define the physiologic effects that occur when the human hair follicle and surrounding tissue structures are exposed to laser light using a novel device that is fitted with an array of laser diode

2017 Dermatologic Surgery

63. Plated-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis. (PubMed)

for androgenic alopecia might be associated with an increased number of hairs and some hair thickness improvement in the treated areas with minimal morbidity. The results of this meta-analysis should be interpreted with caution as it consists of pooling many small studies. Larger randomized studies can verify this perception.© 2017 Wiley Periodicals, Inc. (...) Plated-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis. The use of platelet-rich plasma (PRP) has increased among different surgical specialities for the treatment of various conditions. Androgenetic alopecia is a common condition, with severe attendant psychosocial implications. PRP injections for hair restoration have become a popular practice among plastic surgeons. We performed a meta-analysis comparing local injection of platelet-rich plasma versus control

2017 Journal of cosmetic dermatology

64. Role of Vitamin D in Androgenetic Alopecia

pattern,7 grades) and the Ludwig system for females which classify the Female Pattern Hair Loss into three grades depending on the reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. Etiopathogenesis of Androgenetic Alopecia has not yet been fully elucidated. Genetic factors, hair follicle cycle abnormalities, aging process and androgen dependent process including end organ sensitivity have been all incriminated as etiological factors . Dermoscopy has (...) Role of Vitamin D in Androgenetic Alopecia Role of Vitamin D in Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Role of Vitamin D in Androgenetic Alopecia The safety and scientific

2017 Clinical Trials

65. Platelet-rich plasma—an ‘Elixir’ for treatment of alopecia: personal experience on 117 patients with review of literature (PubMed)

Platelet-rich plasma—an ‘Elixir’ for treatment of alopecia: personal experience on 117 patients with review of literature Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery and dermatology. PRP is a simple, cost-effective and feasible treatment option with high patient satisfaction for hair loss and can be regarded as a valuable adjuvant treatment modality for androgenic alopecia and other types of non-scarring alopecias. Authors have

Full Text available with Trip Pro

2017 Stem Cell Investigation

66. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. (PubMed)

Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL.The aim of this study was to assess QoL in patients (n (...)  = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist.Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16.Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did

2011 Journal of American Academy of Dermatology

67. Use of body and beard donor hair in surgical treatment of androgenic alopecia (PubMed)

Use of body and beard donor hair in surgical treatment of androgenic alopecia Follicular unit transplant is a widely used surgical treatment for androgenic alopecia. However, for patients with extensive hair loss (Norwood 5 and above), scalp donor hair are not sufficient to cover all areas of baldness. This study aims to assess suitability of beard and body donor hair when transplanted to the scalp.In 35 male patients having varying degrees of androgenic alopecia, body and beard donor hair were (...) for treating androgenic alopecia. These hairs, however, do not change their colour, curl, and shaft diameter (calibre). Thus, proper planning is a must when using the different types of donor hair for transplanting.

Full Text available with Trip Pro

2013 Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India

68. Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. (PubMed)

Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles. In this study, we prepared a multimodal microemulsion comprising minoxidil (a dihydrotestosterone (...) microemulsion comprising minoxidil, diclofenac, and tea tree oil was significantly superior to minoxidil alone and placebo in terms of stability, safety, and efficacy, and achieved an earlier response in the treatment of androgenic alopecia compared with minoxidil alone in this 32-week pilot study.

Full Text available with Trip Pro

2013 Drug design, development and therapy

69. Cause of Androgenic Alopecia: Crux of the Matter (PubMed)

Cause of Androgenic Alopecia: Crux of the Matter What is wrong with the current understanding of etiopatho genesis of androgenic alopecia (AGA)? What is the most important question to ask to understand AGA? Why is that question skimped? Which findings are interpreted incorrectly? Is there anything that has not been discerned about AGA until today? What are the deceptive factors for investigators? Is it possible to snap the whole view uninterruptedly in one clear picture? Answers and an overview

Full Text available with Trip Pro

2013 Plastic and Reconstructive Surgery Global Open

70. A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01904721 Recruitment Status : Completed First Posted : July 22, 2013 Results First Posted : December 9, 2015 Last Update Posted : March 22, 2016 Sponsor: Allergan

2013 Clinical Trials

71. Androgen Therapy in Women

Androgen Therapy in Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation (...) Close mobile search navigation Article navigation 1 October 2014 Article Contents Article Navigation Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline Margaret E. Wierman 1Department of Medicine (M.E.W.), University of Colorado School of Medicine, Aurora, Colorado 800452Veterans Affairs Research Service (M.E.W.), Denver, Colorado 80220 Search for other works by this author on: Wiebke Arlt 3Centre for Endocrinology, Diabetes, and Metabolism (W.A.), School

2014 The Endocrine Society

72. Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03543189 Recruitment Status : Recruiting

2018 Clinical Trials

73. COMbination of Bipolar Androgen Therapy and Nivolumab

COMbination of Bipolar Androgen Therapy and Nivolumab COMbination of Bipolar Androgen Therapy and Nivolumab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. COMbination of Bipolar Androgen Therapy (...) Cancer Center at Johns Hopkins Collaborator: Bristol-Myers Squibb Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Study Details Study Description Go to Brief Summary: Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy (i.e

2018 Clinical Trials

74. Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells (PubMed)

Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells Prostaglandin D2 (PGD2) and prostaglandin D2 receptor 2 (DP2) is known to be an important factor in androgenetic alopecia (AGA). However, the effect of PGD2 in human dermal papilla cells (hDPCs) is not fully understood. The function of PGD2-induced expression of the androgen receptor (AR), DP2, and AKT (protein kinase B) signal were examined by using real time-PCR (qRT-PCR

Full Text available with Trip Pro

2018 International journal of molecular sciences

75. Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia (PubMed)

Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile.The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment.Open label, multi-center, non-interventional observational study was done

Full Text available with Trip Pro

2016 Annals of dermatology

76. Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Exclusion Criteria: History (...) Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2016 Clinical Trials

77. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women. (PubMed)

A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women. Early androgenetic alopecia (AGA) is patterned hair loss occurring before age 30 years. Early AGA in men is frequently reported as the phenotypic equivalent of polycystic ovarian syndrome (PCOS) in women, which carries the risk of developing obesity, metabolic syndrome, and cardiovascular diseases. Very few studies have been conducted to evaluate (...) . Men who had any established endocrine disorder, diabetes mellitus, or cardiovascular disease and those who took any oral medication or hormonal treatment for hair loss were excluded from the study. The serum concentrations of total testosterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, fasting plasma glucose, and insulin levels were measured. Insulin resistance (IR) and free androgen index

Full Text available with Trip Pro

2016 JAMA dermatology (Chicago, Ill.)

78. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? (PubMed)

Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? Androgenetic alopecia (AGA) is a highly heritable condition, and the most common form of hair loss in men. The phenotype is characterized by an androgen-dependent, progressive loss of hair from the scalp, which may commence during puberty. Up to 80% of European men experience some degree of androgen-dependent hair loss during their lifetime. Current treatment options for AGA have (...) limited efficacy, and improved understanding of the underlying biological causes is required to facilitate novel therapeutic approaches. To date, molecular genetic studies have implicated 12 genomic regions in AGA and identified a number of candidate genes. The latter include those encoding the androgen receptor (AR), the histone deacetylases (HDAC) 4 and 9, and the WNT molecule WNT10A. However, the majority of contributing genetic risk factors still await identification. This review describes

Full Text available with Trip Pro

2016 Experimental Dermatology

79. Factors affecting the severity of central centrifugal cicatricial alopecia. (PubMed)

Factors affecting the severity of central centrifugal cicatricial alopecia. Central centrifugal cicatricial alopecia (CCCA) is a type of scarring hair loss primarily seen in African-American women. The risk factors that affect the severity of disease remain unclear.This study was designed to elucidate risk factors that may be associated with severity of CCCA.A cross-sectional survey study was conducted. Women with biopsy-confirmed CCCA responded to a questionnaire and were grouped according (...) to a photographic scale of central scalp alopecia. The severity of disease was considered: grade 1 and 2 disease was interpreted as early-stage CCCA, and grade 3-5 disease was interpreted as advanced-stage CCCA. Data from the questionnaire were compared with levels of severity to determine the strength of associations with severity of disease.A total of 38 women with biopsy-confirmed CCCA were recruited to participate in this study. Early-stage CCCA was seen in 22 subjects (57.9%), and advanced-stage CCCA

2016 International Journal of Dermatology

80. Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. (PubMed)

Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. Androgenetic alopecia (AGA) is a common heritable and androgen-dependent hair loss condition in men. Twelve genetic risk loci are known to date, but it is unclear which genes at these loci are relevant for AGA. Dermal papilla cells (DPCs) located in the hair bulb are the main site of androgen activity in the hair follicle. Widely used monolayer

Full Text available with Trip Pro

2016 Journal of Investigative Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>